Inhibikase Therapeutics, Inc. announced the appointment of Timothy Pigot as the company’s Chief Commercial and Strategy Officer on August 19, 2025. Mr. Pigot is a veteran biopharma executive with over three decades of experience.
Mr. Pigot most recently served as Chief Commercial Officer of Aerovate Therapeutics, where he led commercial planning and strategy for a therapeutic candidate in PAH. His prior roles include Vice President of Marketing for MyoKardia, where he led commercial launch strategy for mavacamten.
His expertise in the PAH market landscape and connections with key thought leaders are expected to be invaluable as Inhibikase advances IKT-001 toward a late-stage clinical trial. This appointment strengthens the company's leadership team for its lead program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.